$18.59
-0.28 (-1.51%)
Seattle Genetics, Inc. (NASDAQ:SGEN)
CAPS Rating:
A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.
A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.